Global Urea Cycle Disorders Treatment Market Share Analysis 2024, Forecast To 2033
8 Mar, 2024
The urea cycle disorders treatment market has seen steady growth, rising from $1.29 billion in 2023 to $1.35 billion in 2024, with a CAGR of 4.5%. This growth is attributed to improvements in newborn screening and emergence of patient support networks. Forecasts indicate steady growth, with the market expected to reach $1.57 billion in 2028, boasting a CAGR of 3.9%. Key drivers include advancements in enzyme replacement therapy and expanded newborn screening programs. Major trends include advanced gene editing techniques and personalized nutritional therapies.
Global Urea Cycle Disorders Treatment Market Key Driver
The urea cycle disorders treatment market is expanding due to the rise in the prevalence of urea cycle disorders. Genetic factors contribute to the increasing prevalence of urea cycle disorders, necessitating specialized treatments. Data from StatPearls Publishing LLC and the National Library of Medicine highlight the prevalence of urea cycle disorders, indicating a significant market driver for urea cycle disorders treatments.
Get A Free Sample Of The Global Urea Cycle Disorders Treatment Market ReportGlobal Urea Cycle Disorders Treatment Market Segments
The urea cycle disorders treatment market covered in this report is segmented –
1) Treatment:Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments
2) Enzyme Deficiency:Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1)
3) Route of Administration:Oral, Injectables
4) Distribution Channel:Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The countries covered in the urea cycle disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the urea cycle disorders treatment market in 2023. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Urea Cycle Disorders Treatment Industry Players
F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi S.A.; AstraZeneca Plc.; Alexion Pharmaceuticals Inc.; Abbott Laboratories Inc.; GlaxoSmithKline Plc; Takeda Pharmaceutical Co. Ltd.; Danone S.A.; Merck KGaA; Bausch Health Companies Inc.; Grifols S.A.; Horizon Therapeutics Plc; Leadiant Biosciences Inc.; BioMarin Pharmaceutical Inc.; Ultragenyx Pharmaceutical Inc.; Travere Therapeutics Inc.; Arcturus Therapeutics Holdings Inc.; Selecta Biosciences Inc.; Nutricia North America; Acer Therapeutics Inc.; Aeglea BioTherapeutics Inc; Synlogic Inc.; Lucane Pharma SA; Recordati Rare Diseases Inc.; Orpharma Pty Ltd.; Mead Johnson & Company LLC
Get The Full Global Urea Cycle Disorders Treatment Market Report
Urea Cycle Disorders Treatment Market Overview
Urea cycle disorder treatment refers to managing rare genetic diseases where the body lacks the enzymes necessary to break down ammonia, causing it to build up and potentially be poisonous. The objective of urea cycle disorder treatment is to reduce blood ammonia levels.